To meet this end, CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the «bench - to - beside» approach to develop and improve cancer
immunotherapy in the form of
cellular therapy, a vaccine or targeting antibody, either alone or in combination
with conventional therapies or newly developed therapies.
With DriverMap, Cellecta offers a novel, comprehensive end - to - end service portfolio for identifying differential gene expression, mapping of clinically actionable mutations in RNA, detecting
cellular composition, and profiling
immunotherapy targets.